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Pathologic splenic ruptures re a rare and life-threatening complication of acute
leukemia.
1,2 A splenic rupture as the initial manifestation of acute myeloid leukemia
is extremely rare, and only a few cases have been reported thus far in worldwide
literature.
3-5 It is an abdominal emergency which requires immediate diagnosis via
an abdominal ultrasound and prompt splenectomy in order to ensure the survival
of the patient. In this study, we describe a case of a pathologic splenic rupture as
the initial manifestation of acute myeloid leukemia (AML) M2. 
A 35-year old man was admitted to our hospital with a four-day history of peri-
umbilical pain with dyspepsia and abdominal distension. The patient had no
history of trauma. Upon physical examination, we noted generalized guarding
with tenderness and rebound tenderness over the upper abdomen. The enhanced
computed tomography (CT) scan of the abdomen/pelvis indicated multiple
splenic lacerations, hepatosplenomegaly, and fluid collections in the perihepatic,
perisplenic, both paracolic gutters, and pelvic cavity (Fig. 1). 
The patient underwent a splenectomy. The operative finding was a massively
enlarged spleen with multiple transverse lacerations. The microscopic findings of
the spleen revealed diffuse infiltration of myeloperoxidase (MPO)-stained leuke-
mic blasts (Fig. 2). His complete blood count (CBC) revealed the following: total
white blood cell count of 21,099/µL, hemoglobin of 7.6 g/dL, and platelet count
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A pathologic splenic rupture refers to a rupture without trauma. A splenic rupture as the initial manifestation of
acute myeloid leukemia is extremely rare. In this study, we described a rare case of acute myeloid leukemia present-
ing principally as an acute abdomen due to a pathologic splenic rupture in a 35-year old male patient. We can assert
that a pathologic splenic rupture in hematologic diseases is a potentially life-threatening complication, which
necessitates immediate operative intervention. Any such patient complaining about left upper abdominal tenderness
should be closely observed, and further diagnostic investigations (ultrasonograph of the abdomen, abdominal CT
scan) should be initiated in order to rule out a splenic rupture. The oncologist should be aware of this rare initial
presentation of acute myeloid leukemia (AML) M2, as the condition generally necessitates a prompt splenectomy.
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INTRODUCTION
CASE REPORTof 22,000/µL. On his disseminated intravascular coagulo-
pathy (DIC) profile, prothrombin time (PT) 1.2, internatio-
nal normalized ratio (INR), activated partial thrombo-
plastin time (aPTT) 27.6 seconds, fibrinogen 254 mg/dL,
Fibrinogen degradation product (FDP) 75.8 µg/mL, and D-
dimer > 16 µg/mL - these findings suggested DIC. He
transfused 10 units of packed red blood cell (RBC) (320 mL)
and 30 units of platelet concentrates (320 mL) for operation.
The patient’s peripheral blood smear showed neutrophilic
leukocytosis with leukoerythroblastosis, microcytic anemia,
and marked thrombocytopenia. The patient was subjected
to a bone marrow biopsy examination. The bone marrow
examination revealed a hypercellular marrow of approxi-
mately 70-80% cellularity. Normal myelopoiesis and
erythropoiesis were both depressed, and no megakary-
ocytes were observed. We noted a marked proliferation of
leukemic blasts, 48.6% of all nucleated cells, characterized
by a high nuclear/cytoplasm ratio, fine nuclear chromatin,
several distinct nucleoli, irregular nuclear and cytoplasmic
membranes, and occasional cytoplasmic granules (Fig. 3).
The leukemic blasts were shown to be positive for CD13,
CD33, and CD56, and were also positive for MPO and
PAS. Conventional cytogenetic analysis on the G-banded
metaphases revealed the following: 46,XY,der(7)t(7;9)
(p22;p21)inv(9)(p12q 13),der(9)t(7;9)inv(9). The results
revealed AML of M2 subtype.
Splenic Rupture of AML M2
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Fig. 1. Computed tomography (CT) image of the upper abdomen demonstrates multiple splenic lacerations evidenced by the irregular, non-
homogeneous, low density of splenic body (red arrows). 
Fig. 2.(A) The spleen shows blood clots attached to the ruptured capsule  (H-E stain, ×20). (B) The spleen evidences diffuse invasion by immature
myeloid cells (H-E stain, ×200). (C) The infiltrates are composed principally of myeloperoxidase-positive immature myeloid cells (Myeloperoxidase
stain, ×400).
ABC
Fig. 3. (A) This section shows hypercellular marrow with a cellularity of 70-80% and a diffuse infiltration of leukemic blasts (H-E stain, ×400). (B)
Leukemic blasts tested positive for myeloperoxidase (Myeloperoxidase stain, ×1,000). (C) Leukemic blasts tested positive for PAS (PAS stain, ×1,000).
ABCTen days after the splenectomy, the patient was treated
with an induction of chemotherapy using cytosine-arabi-
noside (100 mg/m
2, days 1-7) and idarubicin (12 mg/m
2,
days 1-3). He was subsequently treated with two cycles of
consolidation chemotherapy using cytosine-arabinoside (3
g/m
2, days 1-3) and idarubicin (12 mg/m
2, days 1-2). The
patient achieved complete remission, but then relapsed
after 5 months. Reinduction chemotherapy using a FLAG-
IDA regimen
6 - fludarabine (30 mg/m
2, days 1-5), cytosine-
arabinoside (2 g/m
2, days 1-7), and idarubicin (10 mg/m
2,
day 1-3) failed to induce remission. The patient was then
treated with two more cycles of reinduction chemotherapy,
but did not achieve complete remission. He was in a refrac-
tory AML state and suffered from intra-abdominal abscess,
abdominal pain, and severe hepatomegaly. Due to his low
performance status, further chemotherapy could not be
administered, and the patient was treated with supportive
care.
A pathologic splenic rupture refers to rupture without
trauma. A normal spleen does not rupture in the absence of
trauma. Therefore, any “spontaneous” rupture should
prompt a search by the clinician for any underlying splenic
pathology.
7
The majority of clinical symptoms of a splenic rupture
include abdominal pain, abdominal tenderness and rigidity,
hypotension, tachycardia, nausea and vomiting, dizziness,
and syncope.
1 The diagnosis of this condition is based on
clinical signs and confirmatory diagnostic tests. Using
ultrasonography or a CT and peritoneal aspirations of fresh
blood may facilitate the diagnosis of  apathological splenic
rupture. CT imaging of the abdomen, although it is unsui-
table for hemodynamically unstable patients, is currently
the imaging method of choice. It is relatively rapid and
accurate, and presents minimal risk to the patient.
8
The exact etiology of a splenic rupture in hemotologic
malignancies remains to be firmly established. The possible
mechanisms suggested thus far include splenic enlarge-
ment, leukemic blasts infiltration of the splenic capsule,
splenic infarction resulting in capsular hemorrhage, and
leukemia-associated coagulopathy.
8 Male patients, patients
above 20 years of age, patients displaying splenomegaly,
and those who have recently undergone cytoreductive che-
motherapy appear to be at higher risk of suffering a patho-
logic rupture.
1
Splenectomy is constituted the treatment of choice for
adults with leukemia and a pathologic splenic rupture.
Splenorrhaphy and partial splenectomy are generally thou-
ght to play no role in the management of pathologic splenic
ruptures in leukemia patients. Without surgical interven-
tion, the mortality rate reported in this population appro-
aches 100%.
2 Therefore, early surgical intervention and
appropriate hemoderivative support is most important.
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